532934-93-3

Basic information

• Product Name: 4-IODO-2-METHYL-6-NITROBENZENAMINE
• Synonyms: 4-IODO-2-METHYL-6-NITROBENZENAMINE;4-Iodo-2-methyl-6-nitroaniline
• CAS NO: 532934-93-3
• Molecular Formula: C₇H₇IN₂O₂
• Molecular Weight: 278.04715
• Mol File: 532934-93-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 366.3°C at 760 mmHg
• Flash Point: 175.3°C
• Appearance: /
• Density: 1.959g/cm³
• Vapor Pressure: 1.48E-05mmHg at 25°C
• Refractive Index: 1.698
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-IODO-2-METHYL-6-NITROBENZENAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-IODO-2-METHYL-6-NITROBENZENAMINE(532934-93-3)
• EPA Substance Registry System: 4-IODO-2-METHYL-6-NITROBENZENAMINE(532934-93-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 532934-93-3(Hazardous Substances Data)

Usage

General Description

4-IODO-2-METHYL-6-NITROBENZENAMINE is a chemical compound with the molecular formula C7H7IN2O2. It is a yellow to orange solid that is commonly used in organic synthesis and pharmaceutical research. 4-IODO-2-METHYL-6-NITROBENZENAMINE is an aromatic amine derivative that contains an iodo and nitro group, making it useful for various applications in the production of pharmaceuticals, dyes, and agrochemicals. It is important to handle this compound with caution as it may pose health risks and environmental hazards if not handled properly.

InChI:InChI=1/C7H7IN2O2/c1-4-2-5(8)3-6(7(4)9)10(11)12/h2-3H,9H2,1H3

Upstream product

• 570-24-1 2-Methyl-6-nitroaniline 
• 7790-99-0 Iodine monochloride 
• 64-19-7 acetic acid 

Downstream Products

• 880762-08-3 1-(4-amino-3-methyl-5-nitrophenyl)pyridin-2(1H)-one 
• 936939-28-5 4-(7-ethyl-2,7-diaza-spiro[4.4]non-2-yl)-2-methyl-6-nitro-phenylamine 
• 936939-22-9 (4-amino-3-methyl-5-nitro-phenyl)-difluoro-acetic acid ethyl ester 
• 936939-29-6 4-(8-benzyl-2,8-diaza-spiro[5.5]undec-2-yl)-2-methyl-6-nitro-phenylamine 
• 532934-96-6 6-iodo-8-methylquinoxaline 
• 1643440-41-8 N-(2,5-diiodo-3-methylphenyl)(hydroxyimino)acetamide 
• 1643440-43-0 6-methyl-4,7-bis(o-tolyl)isatin 
• 1643440-45-2 5-methyl-2-(3-methylbutoxy)-4,7-bis(o-tolyl)-1,3-benzodithiole 
• 1643440-50-9 4-methyl-3,6-bis(o-tolyl)-1,2-benzenedisulfonimide 
• 866996-39-6 2,5-diiodo-3-nitrotoluene 
• 860751-92-4 2,5-diiodo-3-methylaniline 

Relevant articles and documents

Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles

Molecular hybridization is a powerful strategy in drug discovery. A series of novel diarylbenzopyrimidine (DABP) analogues were developed by the hybridization of FDA-approved drugs etravirine (ETR) and efavirenz (EFV) as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). Substituent modifications resulted in the identification of new DABPs with the combination of the strengths of the two drugs, especially compound 12d, which showed promising activity toward the EFV-resistant K103N mutant. 12d also had a favorable pharmacokinetic (PK) profile with liver microsome clearances of 14.4 μL/min/mg (human) and 33.2 μL/min/mg (rat) and an oral bioavailability of 15.5% in rat. However, its activity against the E138K mutant was still unsatisfactory; E138K is the most prevalent NNRTI resistance-associated mutant in ETR treatment. Further optimizations resulted in a highly potent compound (12z) with no substituents on the phenyl ring and a 2-methyl-6-nitro substitution pattern on the 4-cyanovinyl-2,6-disubstitued phenyl motif. The antiviral activity of this compound was much higher than those of ETR and EFV against the WT, E138K, and K103N variants (EC50 = 3.4, 4.3, and 3.6 nM, respectively), and the cytotoxicity was decreased while the selectivity index (SI) was increased. In particular, this compound exhibited acceptable intrinsic liver microsome stability (human, 34.5 μL/min/mg; rat, 33.2 μL/min/mg) and maintained the good PK profile of its parent compound EFV and showed an oral bioavailability of 16.5% in rat. Molecular docking and structure-activity relationship (SAR) analysis provided further insights into the binding of the DABPs with HIV-1 reverse transcriptase and provided a deeper understanding of the key structural features responsible for their interactions.

HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS

-